We are monitoring the impact of COVID-19 on Latin America Parkinson’s Disease Treatment Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 7153
Share on
Share on

Latin America Parkinson’s Disease Treatment Market Research Report – Segmented By Drug Class, Distribution Channel, Patient Care Setting & Country (Brazil, Mexico, Argentina, Chile & Rest of Latin America) – Industry Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 7153
Pages: 145

The size of Latin America Parkinson’s Disease Treatment Market was worth USD 0.54 billion in 2021 and is estimated to be growing at a CAGR of 5.98%, to reach USD 0.72 billion by 2026.

Parkinson's disease is a long-term degenerative disorder of the central nervous system, which chiefly affects the motor system. The symptoms usually come on slowly with time. In the earlier stages of the disease, the most obvious are rigidity, shaking, slowness of movement, and difficulty walking. Thinking and behavioral problems may also occur. Dementia becomes common during the advanced stages of the disease. Anxiety and depression are also commonly occurring in more than a third of people with this disease. Other symptoms include sleep, sensory, and emotional problems.

The cause of Parkinson's disease is usually unknown, but it is believed to involve both environmental and genetic factors. Those who have a family member affected are more likely to get the disease themselves. There is also a higher risk in people exposed to certain pesticides and those who have had prior head injuries, while there is a reduced risk in tobacco smokers and those who drink tea or coffee. The disease's motor symptoms result from cell death in the substantia nigra, which is a region of the midbrain. This results in fewer amounts of dopamine in these areas. Diagnosis of typical cases is mainly based on symptoms, with neuroimaging tests used to rule out other diseases.

The Latin American Parkinson’s Disease Treatment market's driving factors are growth in the aging population and the associated increase in the prevalence of Parkinson's disease, and government funding for research. However, the market is constrained by factors such as the availability of alternative options for Parkinson’s disease management.

This research report on Latin American Parkinson’s Disease Treatment Market has been segmented and sub-segmented into the following categories:

By Drug Class: 

  • Dopamine Receptor Antagonists
    • Pramipexole
    • Ropinirole
    • Apomorphine
    • Rotigotine
  • Mono Amine Oxidase Inhibitors
    • Selegiline
    • Rasagiline
  • Carbidopa
  • Anticholinergics
  • Other Drug Classes

By Distribution Channels: 

  • Retailer Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Patient Care Setting:

  • Clinics
  • Hospitals 

By Country:

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Peru
  • Rest of Latin America

Based on the Drug Class, Carbidopa has the largest share in the segment. 

Based on the Distribution Channel, the Hospital pharmacies have the largest share in the segment.

Based on the Patient Care Setting, the market is classified into clinics and hospitals. hospitals have the largest share in this segment. Factors such as the growing geriatric population and increasing government funding for research are expected to drive the region's market growth. 

Some of the major players in the market are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Class                   

                                5.1.1 Dopamine Receptor Antagonists   

                                                5.1.1.1 Pramipexole

                                                5.1.1.2 Ropinirole

                                                5.1.1.3 Apomorphine

                                                5.1.1.4 Rotigotine

                                5.1.2 Mono Amine Oxidase Inhibitors    

                                                5.1.2.1 Selegiline

                                                5.1.2.2 Rasagiline

                                5.1.3 Carbidopa

                                5.1.4 Anticholinergics    

                                5.1.5 Other Drug Classes              

                                5.1.6  Y-o-Y Growth Analysis, By Drug Class          

                                5.1.7  Market Attractiveness Analysis, By Drug Class        

                                5.1.8  Market Share Analysis, By Drug Class         

                5.2 Distribution Channel                               

                                5.2.1 Retailer Pharmacies            

                                5.2.2 Hospital Pharmacies            

                                5.2.3 Online Pharmacies               

                                5.2.4 Y-o-Y Growth Analysis, By Distribution Channel      

                                5.2.5 Market Attractiveness Analysis, By Distribution Channel    

                                5.2.6 Market Share Analysis, By Distribution Channel      

                5.3 Patient Care Setting                

                                5.3.1 Clinics        

                                5.3.2 Hospitals  

                                5.3.3 Y-o-Y Growth Analysis, By Patient Care Setting       

                                5.3.4  Market Attractiveness Analysis, By Patient Care Setting    

                                5.3.5  Market Share Analysis, By Patient Care Setting      

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Drug Class

                                                6.1.3.2 By Distribution Channel

                                                6.1.3.3 By Patient Care Setting

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Drug Class

                                                6.1.4.2 By Distribution Channel

                                                6.1.4.3 By Patient Care Setting

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Drug Class

                                                6.1.5.2 By Distribution Channel

                                                6.1.5.3 By Patient Care Setting

                6.2 Brazil                             

                6.3 Mexico                         

                6.4 Rest of Latin America                             

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Teva                              

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Novartis AG                                

                8.3 GSK                                

                8.4 AbbVie                         

                8.5 Merck                           

                8.6 Boehringer Ingelheim                            

                8.7 Impax Laboratories                 

                8.8 Lundbeck                    

                8.9 Sun Pharma                                

                8.10 Wockhardt                               

                8.11 UCB                             

                8.12 Valeant Pharmaceuticals                    

                8.13 Acadia                        

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms By Drug Class along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market


Latin America Parkinson’s Disease Treatment Market, By Drug Class, From 2021 to 2026 ( USD Billion )
Latin America Dopamine Receptor Antagonists Market, By Region, From 2021 to 2026 ( USD Billion )
Latin America Mono Amine Oxidase Inhibitors Market, By Region, From 2021 to 2026 ( USD Billion )
Latin America Carbidopa Market, By Region, From 2021 to 2026 ( USD Billion )
Latin America Anticholinergics  Market, By Region, From 2021 to 2026 ( USD Billion )
Latin America Other Drug Classes Market, By Region, From 2021 to 2026 ( USD Billion )
Latin America Parkinson’s Disease Treatment Market, By Distribution Channel , From 2021 to 2026 ( USD Billion )
Latin America Retailer Pharmacies Market, By Region, From 2021 to 2026 ( USD Billion )
Latin America Hospital Pharmacies  Market, By Region, From 2021 to 2026 ( USD Billion )
Latin America Online Pharmacies Market, By Region, From 2021 to 2026 ( USD Billion )
Latin America Parkinson’s Disease Treatment Market, By Patient Care Setting, From 2021 to 2026 ( USD Billion )
Latin America Clinics  Market, By Region, From 2021 to 2026 ( USD Billion )
Latin America Hospitals Market, By Region, From 2021 to 2026 ( USD Billion )
Brazil Parkinson’s Disease Treatment Market, By Drug Class , From 2021 to 2026 ( USD Billion )
Brazil Parkinson’s Disease Treatment Market, By Distribution Channel , From 2021 to 2026 ( USD Billion )
Brazil Parkinson’s Disease Treatment Market, By Patient Care Setting, From 2021 to 2026 ( USD Billion )
Argentina Parkinson’s Disease Treatment Market, By Drug Class , From 2021 to 2026 ( USD Billion )
Argentina Parkinson’s Disease Treatment Market, By Distribution Channel , From 2021 to 2026 ( USD Billion )
Argentina Parkinson’s Disease Treatment Market, By Patient Care Setting, From 2021 to 2026 ( USD Billion )
Mexico Parkinson’s Disease Treatment Market, By Drug Class , From 2021 to 2026 ( USD Billion )
Mexico Parkinson’s Disease Treatment Market, By Distribution Channel , From 2021 to 2026 ( USD Billion )
Mexico Parkinson’s Disease Treatment Market, By Patient Care Setting, From 2021 to 2026 ( USD Billion )
Rest of Latin America Parkinson’s Disease Treatment Market, By Drug Class , From 2021 to 2026 ( USD Billion )
Rest of Latin America Parkinson’s Disease Treatment Market, By Distribution Channel , From 2021 to 2026 ( USD Billion )
Rest of Latin America Parkinson’s Disease Treatment Market, By Patient Care Setting, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample